Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu strains, to ensure the United States is better prepared for future potential pandemics, according to a recent HHS news release.

such as avian influenza A(H5N1). The company plans to design up to four new pandemic influenza vaccines and test them in Phase I trials. In November 2024, Moderna gained approval from Health ...

The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses. Price Action: MRNA stock is up 5.75% at $36.02 at last check Tuesday.

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made

H5N1 vaccines have been previously licensed, and millions are in the national stockpile. But even with the news of the country’s first human death due to bird flu, vaccination isn’t yet recommended.